Indegene Limited has formally notified stock exchanges about an upcoming board meeting scheduled for January 29, 2026, to review the company's third-quarter financial performance. The announcement, made on January 22, 2026, outlines the key agenda items and regulatory compliance measures surrounding the financial results disclosure.

Board Meeting Agenda

The board meeting will address several critical matters related to the company's financial reporting and employee compensation schemes. The primary focus will be on reviewing and approving the unaudited financial results for the quarter ended December 31, 2025.

Regulatory Compliance and Trading Window

In adherence to SEBI (Prohibition of Insider Trading) Regulations, 2015, Indegene Limited has implemented a trading window closure to prevent any potential insider trading activities. The trading window for the company's securities was closed effective January 1, 2026, and will remain closed until 48 hours after the official declaration of the unaudited financial results.

This precautionary measure ensures compliance with regulatory requirements and maintains market integrity during the financial results preparation and announcement period. The trading window closure affects all trading activities in the company's securities on both BSE and NSE.

Financial Reporting Standards

The company will prepare both consolidated and standalone financial results according to Indian Accounting Standards (INDAS). The consolidated results will encompass the financial performance of Indegene Limited and its subsidiaries, providing a comprehensive view of the group's overall financial position. The standalone results will focus specifically on the parent company's individual performance.

Both sets of financial results will be accompanied by limited review reports from the company's auditors, ensuring the accuracy and reliability of the financial information presented to stakeholders.

Corporate Communication

The formal notification was signed by Srishti Ramesh Kaushik, Company Secretary and Compliance Officer, and submitted to both BSE Limited and National Stock Exchange of India Limited. The company trades under scrip code 544172 on BSE and trading symbol INDGN on NSE.

Investors and market participants will need to await the board meeting outcome on January 29, 2026, for detailed insights into the company's Q3FY26 financial performance and any decisions regarding the RSU Scheme 2020 allotments.

Indegene Limited has announced the completion of an amalgamation involving two of its step-down subsidiaries in Canada, effective January 01, 2026. The healthcare services company disclosed this corporate restructuring under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Amalgamation Details

The amalgamation involves Indegene Aptilon Services, Inc. and Trilogy Writing & Consulting Inc. (formerly known as Trilogy Writing and Consulting ULC Canada), both 100% held by Indegene, Inc. USA, which is a wholly owned subsidiary of Indegene Limited. The combined entity has been formed as Indegene Healthcare Canada Inc.

Financial Projections

The company has provided projected revenue figures for the amalgamating entities. The combined operations are expected to generate significant revenue in the Canadian market.

Business Operations

The amalgamating entities operate in complementary areas within the healthcare sector. Trilogy specializes in medical writing and regulatory documentation services for pharmaceutical and life-science industries. Indegene focuses on digital-first life-sciences commercialization, providing technology-enabled services to support biopharmaceutical and medical-device companies in bringing therapies to market and engaging healthcare professionals and patients.

Strategic Impact

This internal restructuring represents a strategic consolidation of Indegene's Canadian operations under a unified corporate structure. The amalgamation is classified as a related party transaction conducted without any impact on the shareholding pattern of the listed entity. The move aligns with the company's efforts to streamline its international subsidiary operations and enhance operational efficiency in the Canadian healthcare market.